Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02831257 · ClinicalTrials.gov registry record · Phase 2
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
A Phase 2 study of Meningioma and Neurofibromatosis 2, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT02831257: Completed Phase 2 study of Meningioma and Neurofibromatosis 2, sponsored by Massachusetts General Hospital.
NCT02831257 is a Phase 2 study of Meningioma and Neurofibromatosis 2 that has completed, run by Massachusetts General Hospital. The registered enrollment target is 18 participants, below the 99-participant average among 21 other Meningioma trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02831257, a Phase 2 study of Meningioma and Neurofibromatosis 2, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.
Primary Outcome
Number of Target Meningiomas with a Decrease in Tumor Volume of at least 20% Compared with Baseline
Conditions Studied
Interventions
- DRUG AZD2014
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 2 |
What the finished NCT02831257 record still lists
NCT02831257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 99-participant average among 21 other Meningioma trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Meningioma appearing as the primary indexed condition, and to 1 intervention - of which AZD2014 is the first listed.
NCT02831257 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02831257 about?
NCT02831257 is a clinical study titled "AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas". The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.
What is the current status of trial NCT02831257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-08-31. Estimated completion is 2020-10-01.
What conditions does trial NCT02831257 study?
This clinical trial studies the following conditions: Meningioma, Neurofibromatosis 2.
What interventions are being tested in trial NCT02831257?
The interventions under investigation include: AZD2014 (DRUG).
Who is sponsoring clinical trial NCT02831257?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02831257 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02831257's enrollment target sits among peer trials
18 21st of 21 higher than 1 of 21 other Meningioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
Monthly SOM230C for Recurrent or Progressive Meningioma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI